September 27, 2020

The Niche

Knoepfler lab stem cell blog

Amgen stem cells

2 min read

I can see many reasons to be jolly on the regenerative medicine front as we get deeper into the holiday season as there is quite a lot of stem cell good news even if there is also some not so good news. In today’s post the focus is on the good news of late. Semma Therapeutics, a stem cell diabetes biotech, raised more than $110 million. I’m eager to see how the next few years play out with the healthy competition between them, ViaCyte, & …Read More